Secondary Logo

Journal Logo

Most Popular Articles

Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY

Potkin, Steven G.; Loze, Jean-Yves; Forray, Carlos; More

International Clinical Psychopharmacology. 32(3):147-154, May 2017.

Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders

Fineberg, Naomi A.; Hollander, Eric; Pallanti, Stefano; More

International Clinical Psychopharmacology. 35(4):173-193, July 2020.

A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder

Fagiolini, Andrea; Albert, Umberto; Ferrando, Laura; More

International Clinical Psychopharmacology. 35(3):137-146, May 2020.

Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder

Fineberg, Naomi A.; Baldwin, David S.; Drummond, Lynne M.; More

International Clinical Psychopharmacology. 33(6):334-348, November 2018.

Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia

Singh, Arun; Gopal, Srihari; Kim, Edward; More

International Clinical Psychopharmacology. 33(4):213-216, July 2018.

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies

Weiss, Catherine; Weiller, Emmanuelle; Baker, Ross A.; More

International Clinical Psychopharmacology. 33(5):255-260, September 2018.

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies

Earley, Willie; Durgam, Suresh; Lu, Kaifeng; More

International Clinical Psychopharmacology. 32(6):319-328, November 2017.

A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan

Higuchi, Teruhiko; Kamijima, Kunitoshi; Nakagome, Kazuyuki; More

International Clinical Psychopharmacology. 31(1):8-19, January 2016.

Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial

Kasper, Siegfried; Gastpar, Markus; Müller, Walter E.; More

International Clinical Psychopharmacology. 25(5):277-287, September 2010.

Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review

Albert, Umberto; Carmassi, Claudia; Cosci, Fiammetta; More

International Clinical Psychopharmacology. 31(5):249-258, September 2016.

Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials

Thase, Michael E.; Edwards, John; Durgam, Suresh; More

International Clinical Psychopharmacology. 32(5):281-288, September 2017.

Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate

Montalvo, Itziar; Ortega, Laura; López, Xavi; More

International Clinical Psychopharmacology. 28(1):46-49, January 2013.

Rapid improvement of obsessive-compulsive disorder associated with schizophrenia with cariprazine add-on in a subject under paliperidone long-acting injection: a case report

De Berardis, Domenico; Vellante, Federica; Fornaro, Michele; More

International Clinical Psychopharmacology. 35(2):113-118, March 2020.

Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial

Mico’, Umberto; Bruno, Antonio; Pandolfo, Gianluca; More

International Clinical Psychopharmacology. 26(6):303-310, November 2011.

D-cycloserine does not enhance exposure–response prevention therapy in obsessive–compulsive disorder

Storch, Eric A.; Merlo, Lisa J.; Bengtson, Michael; More

International Clinical Psychopharmacology. 22(4):230-237, July 2007.

Show: